Long‐chain fatty acids in sarcopenia patients with cardiovascular diseases: importance of n‐9 monounsaturated fatty acids
JCSM Clinical Reports · 2020
DOI: 10.1002/crt2.27 ↗Kurz gefasst
Fachartikel in der Zeitschrift JCSM Clinical Reports, 2020. Verfasst von Atsushi Katoh und 8 weiteren Autor:innen. Die Arbeit wurde bisher 3-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Background
Long‐chain fatty acids are essential components of the cellular energy supply, cellular membranes, and autacoid synthesis. It has been suggested that long‐chain fatty acids might be involved in the pathophysiology underlying sarcopenia. We investigated the association between sarcopenia and serum long‐chain fatty acid profile in patients with cardiovascular diseases.
Methods
We retrospectively investigated 308 cardiovascular patients [age: 72 ± 12 (mean ± SD), 174 male patients] admitted to our hospital. All patients were evaluated by sarcopenia diagnostic tests and serum free fatty acid analyses.
Results
Seventy‐seven patients (25%) were diagnosed with sarcopenia. Serum fatty acid weight percentages of nervonic acid and erucic acid were elevated in patients with sarcopenia compared with those without. Nervonic acid, which was an independent factor for sarcopenia in binary logistics regression analysis ( B = 2.559, p < 0.001), correlated negatively with skeletal muscle index ( r = −0.331, p < 0.001), gait speed ( r = −0.387, p < 0.001), and handgrip strength ( r = −0.372, p < 0.001). These significant relationships were confirmed in subgroup analyses stratified by age and gender. In receiver operating characteristic curve analysis, the cut‐off of nervonic acid weight percentage for diagnosis of sarcopenia was 1.37% with a sensitivity and specificity of 76.6% and 65.1%, respectively.
Conclusions
Nervonic acid, an n‐9 monounsaturated fatty acid, might serve as a new marker for sarcopenia in patients with cardiovascular diseases. Further studies with larger patient numbers will be needed to determine the roles of long‐chain fatty acids in sarcopenia.
Zitieren
APA
Katoh, A., Ikeda, H., Matsushima, Y., Sasaki, M., Okina, N., Niiyama, H., Harada, H., Nishiyama, Y., & Kai, H. (2020). Long‐chain fatty acids in sarcopenia patients with cardiovascular diseases: importance of n‐9 monounsaturated fatty acids. JCSM Clinical Reports. https://doi.org/10.1002/crt2.27
Vancouver
Katoh A, Ikeda H, Matsushima Y, Sasaki M, Okina N, Niiyama H, et al. Long‐chain fatty acids in sarcopenia patients with cardiovascular diseases: importance of n‐9 monounsaturated fatty acids. JCSM Clinical Reports. 2020. doi:10.1002/crt2.27
BibTeX
@article{Katoh2020,
author = {Katoh, Atsushi and Ikeda, Hisao and Matsushima, Yoshihisa and Sasaki, Motoki and Okina, Norihito and Niiyama, Hiroshi and Harada, Haruhito and Nishiyama, Yasuhiro and Kai, Hisashi},
title = {Long‐chain fatty acids in sarcopenia patients with cardiovascular diseases: importance of n‐9 monounsaturated fatty acids},
journal = {JCSM Clinical Reports},
year = {2020},
doi = {10.1002/crt2.27}
}
EUVIMED